However, the outcome of clinical trials conducted in the last years was controversial: the monoclonal anti-VEGF-A Bevacizumab, for example, appeared as one of the most promising novel agents; however, the promising effect in a neoadjuvant setting, in addiction to chemotherapy, in HER2-negative breast cancer patients [67] was not confirmed by a subsequent clinical study [68]. This evidence concerns the gene ERBB2 and breast cancer.